AstraZeneca, CVGI Medicinal Chemsitry, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK +44 1625 230942 ; +44 1625 516667 ;
Expert Opin Drug Discov. 2010 Mar;5(3):235-48. doi: 10.1517/17460441003605098.
The role of lipophilicity in determining the overall quality of candidate drug molecules is of paramount importance. Recent developments suggest that, as well as determining pre-clinical ADMET (absorption, distribution, metabolism, elimination and toxicology) properties, compounds of optimal lipophilicity might have increased chances of success in development.
The review covers aspects of methods of prediction of lipophilicity in frequent use and describes the most relevant literature analyses linking individual ADMET parameters and more composite measures of overall compound 'quality' with lipophilicity.
The aim is to provide an overview of the relevant literature in an attempt to summarise where the optimum region of lipophilicity lies and to highlight which particular issues and risks might be expected when operating outside this region.
The review of the data shows that this optimal space is defined by a narrow range of logD between ∼ 1 and 3. Some of the implications of this for medicinal chemistry optimisation are discussed.
脂溶性在确定候选药物分子的整体质量方面至关重要。最近的研究表明,除了确定临床前 ADMET(吸收、分布、代谢、消除和毒性)特性外,具有最佳脂溶性的化合物在开发中可能具有更高的成功机会。
本综述涵盖了常用的脂溶性预测方法的各个方面,并描述了将个体 ADMET 参数与整体化合物“质量”的更综合指标与脂溶性联系起来的最相关文献分析。
旨在概述相关文献,试图总结脂溶性的最佳区域,并强调在该区域之外可能会出现哪些特定问题和风险。
对数据的回顾表明,这个最佳空间由 logD 约在 1 到 3 之间的狭窄范围定义。讨论了这对药物化学优化的一些影响。